Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties
- PMID: 32700405
- PMCID: PMC7405045
- DOI: 10.1002/psp4.12550
Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties
Conflict of interest statement
D.S.R. and V.S. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and own stock options in Merck & Co., Inc., Kenilworth, NJ, USA. V.S. also reports stock and patents from Eli Lilly and Co. P.Z. is an employee of the Gates Foundation; the foundation has a grant to INSERM to expand their viral dynamic model.
Figures
Comment on
-
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):509-514. doi: 10.1002/psp4.12543. Epub 2020 Aug 7. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32558354 Free PMC article.
References
-
- Schmith, V.D. , Zhou, J. & Lohmer, L.R. Dimitris Rizopoulos ISBN 10: 1439872864. Chapman and Hall/CRC. ISBN 13: 9781439872864.
-
- Fan, J. et al Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID‐19 patients. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa623. - DOI - PMC - PubMed
-
- Gonçalves, A. et al Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load. CPT Pharma. Syst. Pharmacol. https://doi.org/10.1002/psp4.12543. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous